not used title

not used title

New medicines are revolutionizing how we fight disease, but too often patients have to fight to access innovative treatments. As part of the solution to this problem, biopharmaceutical companies are working with insurers to develop new ways to pay for medicines.

Results-based contracts are an innovative approach to paying for medicines that often involve greater risk-sharing among payers and biopharmaceutical companies. They can also vary payment based on how well medicines work in different populations. As a result of these arrangements, payers can make a medicine more accessible to patients and biopharmaceutical companies agree to share the financial risk and be reimbursed based on how well medicines work for patients.  And the good news is biopharmaceutical companies and insurers are increasingly pursuing these types of arrangements.

 

 

Learn more at www.phrma.org/value-collaborative.

Katie Koziara

Katie Koziara is Senior Director of public affairs at PhRMA focusing on the organization’s executive visibility work and media relations strategy. She previously ran the social media strategy for a D.C.-based non-profit working on federal management and leadership issues. Katie earned her B.A. in Public Policy from the University of Michigan’s Ford School and is currently earning her M.A. in Fiction Writing from Johns Hopkins University.

Katie Koziara

Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change

March 13, 2025

Three things to know about the United Nations’ new HIV/AIDS report

July 31, 2024

Case study: How seniors could face access disruptions because of the IRA’s price setting provisions

July 22, 2024

ICYMI: Misaligned policies undermine patient access

June 6, 2024

Critics repeat same, misleading narrative on potential “costs” of new medicines

May 7, 2024

Insurance data: PBM reform has no material impact on premiums

April 24, 2024

What recent rhetoric on the cost of diabetes and anti-obesity medicines gets wrong

April 9, 2024

3 Takeaways from POLITICO’s Health Care Summit

April 3, 2024

Setting the Record Straight: Comparing U.S. drug prices to those in foreign countries hurts patients

February 7, 2024

When it comes to the future of innovation, the ball is in policymakers’ court

January 22, 2024

New analysis of patient access restrictions in the United Kingdom

November 21, 2023

ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference

November 6, 2023

Incomplete evaluations undermine patient access to transformational medicine

October 5, 2023

AARP’s latest misleading report

August 11, 2023

New report: Hospitals mark up medicine prices 500%

August 2, 2023

read more

August 2, 2023

Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation

July 26, 2023

Key considerations as Congress works towards PAHPA reauthorization

July 12, 2023

Insulin: Key Facts on Access & Affordability

May 10, 2023

4 key facts on medicine prices and spending

May 9, 2023

Three facts about health care spending

April 25, 2023

States can support access to medicine as COVID-19 Public Health Emergency ends

April 5, 2023

Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines

January 31, 2023

ICYMI: Cancer death rate continues to decline due to treatment advances

January 25, 2023

Novel medicines approved in 2022 offer increased treatment options for patients

January 23, 2023

ICYMI: PhRMA kicks off the year at the 2023 J.P. Morgan Health Care Conference

January 19, 2023

Study finds hepatitis C cure saved Medicaid $15 billion

January 5, 2023

In their own words: Insured Americans support policy reforms that address access and affordability concerns

December 14, 2022

New data show how insurers and middlemen shift Rx costs onto patients

November 16, 2022

Busting 3 Myths About Copay Coupons

October 5, 2022

Making coupons count for patients at the pharmacy counter

August 25, 2022

By the Numbers: Patients lose when the government sets prices

July 8, 2022

Prescription drug prices are not fueling inflation

July 6, 2022

CMS coverage decision restricts access to treatments for Alzheimer’s disease

June 22, 2022

You won’t fix what you don’t value: Two reasons why traditional cost-effective analyses can perpetuate health inequities

June 16, 2022

PhRMA warns of the growing influence of middlemen over patient access and out-of-pocket costs for patients

May 31, 2022

PhRMA presents research at ISPOR 2022

May 26, 2022

Report finds PBMs are increasingly restricting patient access to medicines

May 25, 2022

ICYMI: PhRMA CEO Stephen J. Ubl spotlights lessons learned during COVID-19

May 13, 2022

Annual projections from NHE compared to actual health care spending

May 5, 2022

Innovative contracts continue to gain traction and improve quality of care

May 2, 2022

What’s really happening when it comes to prescription drug costs

April 27, 2022

Analysis: States can help patients save nearly $1,000 annually on their medicines

April 21, 2022

New analysis confirms hospitals markup prices for oncology therapies

April 21, 2022

How standardized plans can improve patients’ access to medicines

April 18, 2022

Correcting the record: Putting medicine costs and spending in context

March 24, 2022

Sharing rebates can save Americans with diabetes 500 each year and improve adherence

March 16, 2022

Guest Post: If we truly want to cure complex diseases, politicians should reject price setting

March 14, 2022

Veterans Affairs 101: Three charts show how the VA system differs from Medicare

March 11, 2022

If drug prices are growing below the rate of inflation, why are patients still feeling the sting at the pharmacy?

March 8, 2022

Government price setting leaves behind families counting on new medicines

February 23, 2022

340B 101: Three charts show the program maximizes hospitals’ bottom line with little consideration for patients

February 8, 2022

Research and development continues long after a medicine is initially approved

February 1, 2022

New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”

January 25, 2022

CBO reaffirms our innovation ecosystem leads to improved lives, long-term savings

January 21, 2022

New study finds more than half of brand medicine spending goes to the supply chain and others

January 7, 2022

New NHE data show the true picture of health care spending

December 22, 2021

3 things to know about the importance of post-approval research and development

December 6, 2021

Guest post: Congress should not put future innovation at risk

November 29, 2021

What is missing in the current drug pricing plan

November 23, 2021

ICYMI: PhRMA CEO speaks at STAT Summit about government price setting

November 19, 2021

In the current health care debate, Congress has lost sight of what matters to U.S. voters

November 15, 2021

CMS finds medication adherence saved Medicare up to 46.6B in avoided health care costs between 2013 and 2018

October 19, 2021

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

October 18, 2021

New poll shows Americans reject Medicare negotiation once they learn more about the policy

October 15, 2021

To drive up profits, hospitals continue unnecessary medicine mark-ups, burdening patients, employers and health care system

October 14, 2021

What is Kaiser Family Foundation up to?

October 12, 2021

Recognizing Hepatitis R&D on World Hepatitis Day

July 28, 2021

New reports shed light on key facts about medicines and affordability

June 8, 2021

How strengthening the biosimilar marketplace benefits patients

May 18, 2021

Study finds nearly half of payers believe innovative contracts can lead to lower patient out-of-pocket costs

May 17, 2021

New report demonstrates development of new medicines relies on private sector expertise and investment

May 10, 2021

West Virginia becomes the first state to lower patient costs by sharing the savings

April 20, 2021

Getting the 340B program back on track in 2021

March 10, 2021

Top five issues voters want addressed in the administration’s first 100 days

February 18, 2021

Insurers shift medicine costs to patients with severe chronic illnesses

February 1, 2021

Accumulator adjustment programs lead to surprise out-of-pocket costs and nonadherence, analysis finds

November 19, 2020

Survey found insurance premiums grew faster than inflation in 2020

October 20, 2020

Growth in innovative, value-based contracts holds promise for the health system and for patients

September 24, 2020

Innovative contracts drive access for patients and value for the system

September 9, 2020

Manufacturer cost-sharing assistance programs can save chronically ill patients hundreds to thousands of dollars annually

August 19, 2020

Commercial health plans have increased patients’ out-of-pocket costs by over 50% in some therapeutic areas

August 12, 2020

Commercial health plans transition from copays to coinsurance and deductibles has increased patient out-of-pocket costs

August 6, 2020

Four things to know about the IQVIA “Medicine Spending and Affordability in the U.S.” report

August 5, 2020

New data show commercially insured patients face increasingly high cost sharing for brand medicines

July 30, 2020

Payers subject 80% of new RA and MS patients to utilization management restrictions

July 22, 2020

ICYMI: Pharmacy benefit managers increasingly exclude medicines from formularies, restricting patient access

June 1, 2020

New rule makes it harder for patients to lower their out-of-pocket costs

May 20, 2020

ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements

April 20, 2020

PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs

March 3, 2020

Low-value health care costs $345B each year and provides little benefit

February 26, 2020

Addressing barriers that inhibit value-based contracts

February 21, 2020

Fact Check: HCCI analysis overstates medicine spending and prices

February 19, 2020

Cancer medicines cost twice as much at hospitals, study finds

January 21, 2020

Nearly 50% of brand medicine spending goes to the supply chain and others

January 9, 2020

Guest post: Value-based agreements can improve outcomes and even save patients money at the pharmacy counter

November 7, 2019

New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country

November 4, 2019

More evidence that medicine prices are growing at slowest rate in decades

October 4, 2019

Survey shows out-of-pocket costs top health care concern for voters

October 2, 2019

Four reasons why the radical Pelosi Plan is the wrong approach

September 24, 2019

Hospitals make 9 times more than physicians’ offices on provider-administered medicines

September 10, 2019

Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

September 4, 2019

Three things to know about the Part D GAO report

August 16, 2019

Setting the record straight on international reference pricing

July 16, 2019

New Let’s Talk About Cost TV ad asks: Why aren’t patients sharing in savings at the pharmacy counter?

July 9, 2019

Study finds hospitals continue to mark up medicines up to 500% of their cost

July 9, 2019

Three reasons why the latest Rx Savings Solutions analysis is misleading

July 2, 2019

"If Washington isn’t careful, we might leave innovation behind"

June 24, 2019

5 Ways to improve ICER’s value assessment framework

June 20, 2019

Assessing value top of mind at ISPOR 2019

June 5, 2019

Ask About Adherence: OIG proposed rule to reform the rebate system could improve adherence

May 15, 2019

New study finds hospitals continue to push patients to costlier outpatient settings

May 13, 2019

4 Things to know about the IQVIA “Medicine Use and Spending” report

May 9, 2019

Meet MAT: 5 things to know about PhRMA’s new “Medicine Assistance Tool”

May 9, 2019

Fact Check: How the Part B International Pricing Index model threatens patient access

March 29, 2019

New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid

March 20, 2019

The PBM story you haven’t heard: Hidden fees quadrupled in two years

March 20, 2019

Value assessments should include all the outcomes that matter to patients and families

February 20, 2019

Health Affairs study misses the mark on medicine costs

January 28, 2019

PhRMA comments to administration on Medicare Part D proposed rule

January 25, 2019

New government data show medicine price growth continues to decline

January 18, 2019

ICYMI: New study reinforces dangers of proposed IPI model

January 15, 2019

Groups sound the alarm on administration’s new Part B proposal

November 14, 2018

4 things you need to know about the administration’s latest Part B proposal

November 5, 2018

PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation

November 2, 2018

Americans want to know more than just the list price of a medicine—and we’re answering their call

October 15, 2018

What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising

October 15, 2018

Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles

October 4, 2018

Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care

October 2, 2018

Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program

September 24, 2018

New whitepaper identifies reasons why ICER’s cost-effectiveness analyses are not useful for payers

September 19, 2018

What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?

September 13, 2018

Guest post: Developing new payment models to ensure patients have access to high-investment therapies

September 6, 2018

New study finds some hospitals mark up medicine prices at least 700 percent

September 5, 2018

Number of value-based contracts continues to rise

August 27, 2018

69 percent of patients abandon medicines when cost sharing is more than $250

August 23, 2018

New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain

August 13, 2018

How much do you know about Medicare Part B?

July 31, 2018

ICER’s budget impact threshold: Sounding a false alarm on affordability and access

July 24, 2018

PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

July 16, 2018

Event next week: Supporting the next generation of lifesaving medicines

July 12, 2018

How ICER’s assessment of a new class of migraine treatments fails patients

July 10, 2018

New data show patients’ out-of-pocket costs are rising faster than their insurers’ costs

July 9, 2018

Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge

June 28, 2018

Aspen Spotlight Health: Discussing the forefront of innovation

June 21, 2018

Medicare Part D cliff ahead

June 21, 2018

Part D cliff looms for seniors, as program stability could be in jeopardy

June 18, 2018

New analysis shows that more medicines worldwide are available to U.S. patients

June 5, 2018

New analysis shows that HTA organizations may frequently restrict access to cancer treatments

June 1, 2018

New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B

May 31, 2018

ICYMI: Recent survey adds to growing body of research on barriers to innovative payment approaches

May 29, 2018

Event tomorrow: Improving patient access to lifesaving medicines

May 22, 2018

Sharing negotiated discounts at the pharmacy counter could save seniors with diabetes more than $350 annually

May 17, 2018

New “Let’s Talk About Medicare” campaign focuses on solutions to improve affordability and predictability for seniors in Part D

May 9, 2018

Video: PhRMA CEO discusses biopharmaceutical supply chain at POLITICO event

May 4, 2018

Event tomorrow: Making the biopharmaceutical supply chain work for patients

May 2, 2018

Reality check: Value-based contracts are good for patients

April 25, 2018

Spending on medicines grew less than one percent in 2017

April 19, 2018

Video: Barriers to results-based contracts

April 17, 2018

Patients pay the price when hospitals mark up cancer medicines

April 5, 2018

PPA celebrates 13 years of helping patients access their medicines

April 5, 2018

Advance price notification: A transparency measure that fails patients

March 29, 2018

New Let’s Talk About Cost ads highlight how copay accumulator programs could leave patients financially exposed

March 27, 2018

Improving care quality by engaging patients in shared decision making

March 22, 2018

Video: How does the supply chain shape brand-name medicine prices?

March 19, 2018

ICYMI: Research shows promise of innovative payment arrangements in reducing costs, improving access

March 15, 2018

4 Things to know about the IQVIA 2018 and Beyond: Outlook and Turning Points report

March 13, 2018

ICYMI: Two PBM reports show dramatic slowdown in medicine spending growth

March 2, 2018

Copay coupons can help ease patients’ out-of-pocket costs

February 16, 2018

Oregon’s HB 4005 fails to deliver savings for patients

February 14, 2018

PhRMA launches new consumer-facing Let’s Talk About Cost website

January 24, 2018

Clarity around anti-kickback statute needed to promote innovative payment arrangements

January 10, 2018

NHE Data: Medicine spending grew just 1.3 percent in 2016

December 12, 2017

Excerpts from testimony by PhRMA’s Lori Reilly

October 17, 2017

How much are hospitals marking up the price of medicines? The answer may surprise you.

October 17, 2017

PhRMA Foundation recognizes inaugural Challenge Award recipients

October 6, 2017

4 things to know about the QuintilesIMS drivers of medicine spending in the U.S. report

September 28, 2017

Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care

September 21, 2017

The journey to better health care requires a holistic view

September 18, 2017

What they are saying: Study on cancer R&D costs is not an accurate representation of marketplace

September 12, 2017

Video: PhRMA CEO discusses medicine costs with CNBC's Squawk Box

July 31, 2017

Medicare Monday: How Part B has evolved over the years

July 24, 2017

New PhRMA resources chock full of biopharma industry facts

July 20, 2017

New “Let’s Talk About Cost” campaign convenes national dialogue on medicine costs

July 12, 2017

New data put medicine costs and spending in context

June 26, 2017

In the OECD other health care services will be ten times prescription medicine spending growth over next decade

June 14, 2017

Modernizing FDA regulations to advance a value-driven health care system

June 8, 2017

Foreign government price setting by any name harms innovation and access to medicines

June 6, 2017

PhRMA CEO in Forbes - How to negotiate better deals for prescription medicines

June 2, 2017

ICYMI: Avalere and FasterCures develop new value framework from patient perspective

May 31, 2017

Medicines have significantly increased chances of cancer survival around the globe

May 24, 2017

Compulsory licensing: A misused and abused international trade law

May 16, 2017

Why won’t the insurance industry tell the truth about medicine costs?

May 10, 2017

Government-imposed price controls threaten innovation and access

May 9, 2017

ICYMI: Innovative payment models helping provide patient access to new medicines

May 5, 2017

4 Things to know about the QuintilesIMS Medicines Use and Spending in the U.S. report

May 4, 2017

RA medicines often demonstrate far greater benefits to patients than initially understood

April 5, 2017